Technology | Radiation Therapy | October 20, 2017

System provides high-dose treatment for various types of skin cancer

Xstrahl Photoelectric Therapy System Receives FDA 510(k) Clearance

October 20, 2017 — Xstrahl announced that its Photoelectric Therapy System has received U.S. Food and Drug Administration (FDA) 510(k) clearance for treatment of skin cancer. The Photoelectric Therapy System is a compact and ergonomic superficial X-ray therapy system operating in the 10kV to 80kV range intended for superficial radiotherapy and surface electronic brachytherapy treatment of primary malignant epithelial neoplasms of the skin and keloids.

Utilizing trusted and clinically proven low energy photons in a dedicated treatment system, the Photoelectric Therapy System provides a pain-free, non-surgical alternative for the treatment of non-melanoma skin cancer and superficial lesions, especially those found in sensitive areas of the head and neck.

Using an ideal depth dose profile for the treatment of superficial skin lesions, the high dose output enables treatment times to be kept to a minimum in the same manner as electronic brachytherapy systems while treating a wider range of skin conditions. The low half-value layer (HVL) of the system allows for higher doses without compromising on depth of delivery.

Typical applications include treatment for:

  • Basal cell carcinoma;
  • Squamous cell carcinoma;
  • Metatypic carcinoma;
  • Cutaneous appendage carcinoma;
  • Karposi's sarcoma;
  • Merkel cell carcinoma;
  • Lentigo maligna;
  • Lentigo maligna melanoma;
  • Cutaneous lymphomas (B and T cell); and
  • Keloids.

The system is freestanding, self-contained, unobtrusive, compact and lightweight, which helps to ensure a reassuring and stress-free patient experience in any clinical facility. The system is mounted on lockable castors, allowing free movement and operation in any clinical space. It features ergonomically designed controls ensuring smooth adjustment and safe, simple patient set-up. The system requires connection to the clinical facilities electrical supply and room interlocks, but generates X-rays using a 24V power supply.

Photoelectric therapy devices require minimal shielding as compared to higher energy X-ray therapy systems.

For more information: www.xstrahl.com


Related Content

News

Aug. 5, 2024 — Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that adding ...

Time August 09, 2024
arrow
News | PET-CT

July 31, 2024 — In a head-to-head comparison with FDG PET/CT, FDG PET/MRI demonstrated comparable or superior diagnostic ...

Time July 31, 2024
arrow
Feature | Radiation Oncology | By Christine Book

News emerging from several leading organizations and vendors in the radiation therapy arena came in at a fast pace in ...

Time July 30, 2024
arrow
News | Radiation Oncology

July 11, 2024 — The American Society for Radiation Oncology (ASTRO) issued the following statement from Jeff M ...

Time July 11, 2024
arrow
News | Prostate Cancer

July 11, 2024 — GE HealthCare’s MIM Software, a global provider of medical imaging analysis and artificial intelligence ...

Time July 11, 2024
arrow
News | Radiation Oncology

July 9, 2024 — Insights from the latest Mordor Intelligence report, “Radiotherapy Market Size & Share Analysis - Growth ...

Time July 09, 2024
arrow
News | Prostate Cancer

July 5, 2024 — Lantheus Holdings, Inc., a leading radiopharmaceutical-focused company committed to enabling clinicians ...

Time July 05, 2024
arrow
News | Radiology Business

July 3, 2024 — The American Society of Radiologic Technologists has launched the BeRAD Professionalism Award to ...

Time July 03, 2024
arrow
News | Prostate Cancer

July 2, 2024 — A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, “Deep learning ...

Time July 02, 2024
arrow
News | Radiation Oncology

June 3, 2024 — The American Society for Radiation Oncology (ASTRO) published an updated clinical guideline that details ...

Time June 03, 2024
arrow
Subscribe Now